Pilot Study for the NorCAPITAL Trial

This study has been completed.
Information provided by (Responsible Party):
Vegard Bruun Wyller, Oslo University Hospital
ClinicalTrials.gov Identifier:
First received: December 22, 2011
Last updated: January 12, 2012
Last verified: January 2012

The aim of this pilot study for the NorCAPITAL trial is to investigate the feasibility and safety of the drug clonidine in adolescent chronic fatigue syndrome (CFS). Specifically, the investigators wanted to assess appropriate dosage in relation to a) plasma concentration levels of clonidine, b) orthostatic cardiovascular responses (the pulse and blood pressure responses when rising up), and c) reports of possible adverse effects.

A possible beneficial effect of clonidine in adolescent CFS will be investigated in NorCAPITAL, which is a randomized, placebo-controlled, double blind trial.

Condition Intervention
Chronic Fatigue Syndrome
Drug: Clonidine

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Pilot Study for the NorCAPITAL Trial

Resource links provided by NLM:

Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Plasma concentration level (Cmax and Co) of clonidine [ Time Frame: After 14 days of treatment ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Orthostatic cardiovascular responses (head-up tilt test) [ Time Frame: After 14 days of treatment ] [ Designated as safety issue: Yes ]
  • Reports of adverse effects [ Time Frame: Participants will be followed for the duration of treatment period, an expected average of 14 days ] [ Designated as safety issue: Yes ]
  • Plasma concentration (Cmax) of clonidine [ Time Frame: First day of treatment, approximately 5 hours after the first dose ] [ Designated as safety issue: Yes ]

Enrollment: 5
Study Start Date: January 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Clonidine Drug: Clonidine
50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.


Ages Eligible for Study:   12 Years to 19 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Persisting or constantly relapsing fatigue lasting 3 months or more
  • Functional disability resulting from fatigue to a degree that prevent normal school attendance
  • Age between 12 and 19 years

Exclusion Criteria:

  • Another disease process or current demanding life event that might explain the fatigue
  • Another chronic disease
  • Permanent use of drugs
  • Permanently bed-ridden
  • Positive pregnancy test
  • Supine systolic blood pressure (SBP) < 85 mm Hg
  • Fall in SPB upon standing > 30 mm Hg
  • Supine HR < 50 beats/min
  • Abnormal ECG
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01507701

Oslo University Hospital Rikshospitalet, Dept. of Pediatrics
Oslo, Norway, NO-4950
Sponsors and Collaborators
Oslo University Hospital
Principal Investigator: Vegard Bruun Wyller, MD, PhD Oslo University Hospital Rikshospitalet, Dept. of Pediatrics
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Vegard Bruun Wyller, Associate Professor, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01507701     History of Changes
Other Study ID Numbers: NorCAPITALps 
Study First Received: December 22, 2011
Last Updated: January 12, 2012
Health Authority: Norway: Norwegian Medicines Agency

Keywords provided by Oslo University Hospital:

Additional relevant MeSH terms:
Fatigue Syndrome, Chronic
Central Nervous System Diseases
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Virus Diseases
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Antihypertensive Agents
Autonomic Agents
Cardiovascular Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 05, 2016